SBC Medical Group Holdings Incorporated (SBC) EBITDA
- 2026-06-30: Basis Reported; EBITDA $20.09M*; Operating income $18.96M; Depreciation and amortization $1.13M*.
- 2026-03-31: Basis Reported; EBITDA $18.39M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $13.52M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA $16.63M*; Operating income $15.88M; Depreciation and amortization $746.21K*.
Complete source-backed ebitda history.
- Available history
- 2023-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | $20.09M* | $18.96M | $1.13M* | $49.19M | 40.85%* | $84.40K* | $22.51M* | (m) | (m) | $17.02M | $7.82M |
|---|
| 2026-03-31 | Reported | $18.39M | (m) | (m) | (m) | 42.71% | $125.00K | $9.23M | (m) | (m) | $12.63M | $7.53M |
|---|
| 2025-12-31 | Reported | $13.52M | (m) | (m) | (m) | 34.18% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | $16.63M* | $15.88M | $746.21K* | $43.35M | 38.35%* | $43.05K* | -$20.88M* | (m) | (m) | $14.73M | $5.67M |
|---|
| 2025-06-30 | Reported | $15.19M* | $14.55M | $636.10K* | $43.36M | 35.03%* | $306.71K* | -$8.34M* | (m) | (m) | $15.46M | $11.10M |
|---|
| 2025-03-31 | Reported | $24.83M | (m) | (m) | (m) | 52.46% | $253.72K | $1.93M | (m) | (m) | $13.53M | $9.96M |
|---|
| 2024-12-31 | Reported | $5.65M | (m) | (m) | (m) | 12.72% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | $14.85M* | $13.83M | $1.02M* | $53.08M | 27.98%* | $408.95K* | $5.01M* | (m) | (m) | $16.60M | $10.27M |
|---|
| 2024-06-30 | Reported | $28.12M* | $27.29M | $830.95K* | $53.10M | 52.96%* | $863.05K* | $19.19M* | (m) | (m) | $12.13M | $8.53M |
|---|
| 2024-03-31 | Reported | $25.48M | (m) | (m) | (m) | 46.49% | $702.28K | $3.68M | (m) | (m) | $15.06M | $8.45M |
|---|
| 2023-12-31 | Reported | $26.55M | (m) | (m) | (m) | 42.58% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | (m) | $20.02M | (m) | $47.28M | (m) | (m) | $24.07M* | (m) | (m) | $13.45M | $13.01M |
|---|
| 2023-06-30 | Reported | (m) | -$473.37K | (m) | (m) | (m) | (m) | -$921.18K* | (m) | (m) | (m) | $166.73K |
|---|
| 2023-03-31 | Reported | (m) | -$388.45K | (m) | (m) | (m) | (m) | -$393.82K | (m) | (m) | (m) | $262.69K |
|---|
| 2022-09-30 | Reported | (m) | -$303.62K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $58.65K |
|---|
| 2022-06-30 | Reported | (m) | -$1.28K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | $70.17M | (m) | (m) | (m) | 40.42% | $1.40M | $24.67M | (m) | (m) | $59.80M | $31.02M |
|---|
| 2024-12-31 | Reported | $74.1M | (m) | (m) | (m) | 36.07% | $2.56M | $20.58M | (m) | (m) | $57.67M | $26.77M |
|---|
| 2023-12-31 | Reported | $82.91M | (m) | (m) | (m) | 42.84% | $8.54M | $50.67M | (m) | (m) | $66.23M | $35.02M |
|---|